{
    "root": "fd3a5cc6-5bbe-4690-8d20-f3508a309131",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Trintellix",
    "value": "20250304",
    "ingredients": [
        {
            "name": "VORTIOXETINE HYDROBROMIDE",
            "code": "TKS641KOAY"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "trintellix indicated treatment major depressive disorder ( mdd ) adults .",
    "contraindications": "\u2022 recommended starting dose 10 mg administered orally daily without regard meals ( 2.1 ) . \u2022 dose increased 20 mg/day , tolerated ( 2.1 ) . \u2022 consider 5 mg/day patients tolerate higher doses ( 2.1 ) . \u2022 trintellix discontinued abruptly . however , recommended doses 15 mg/day 20 mg/day reduced 10 mg/day one week prior full discontinuation possible ( 2.3 ) . \u2022 maximum recommended dose 10 mg/day known cyp2d6 poor metabolizers ( 2.5 ) .",
    "warningsAndPrecautions": "trintellix tablets available follows : features strengths 10 mg 20 mg color yellow red debossment `` 10 `` one side tablet `` tl `` side tablet `` 20 `` one side tablet `` tl `` side tablet presentations ndc codes bottles approximately 2520 tablets , ndc 55154-0256-8 bottles approximately 2430 tablets , ndc 55154-0257-8",
    "adverseReactions": "\u2022hypersensitivity vortioxetine component formulation . hypersensitivity including anaphylaxis , angioedema , urticaria reported patients treated trintellix [ ( 6.2 ) ] . \u2022the maois intended treat psychiatric disorders trintellix within 21 days stopping treatment trintellix contraindicated increased risk serotonin syndrome . trintellix within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.4 ) , ( 5.2 ) ] . starting trintellix patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 5.2 ) ] .",
    "indications_original": "TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults.",
    "contraindications_original": "\u2022 The recommended starting dose is 10 mg administered orally once daily without regard to meals ( 2.1 ). \u2022 The dose should then be increased to 20 mg/day, as tolerated ( 2.1 ). \u2022 Consider 5 mg/day for patients who do not tolerate higher doses ( 2.1 ). \u2022 TRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible ( 2.3 ). \u2022 The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers ( 2.5 ).",
    "warningsAndPrecautions_original": "TRINTELLIX tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Features\n                              \n                           \n                           \n                              \n                                 Strengths\n                              \n                           \n                        \n                        \n                           \n                              \n                                 10 mg\n                              \n                           \n                           \n                              \n                                 20 mg\n                              \n                           \n                        \n                        \n                           \n                              Color\n                           \n                           \n                              yellow\n                           \n                           \n                              red\n                           \n                        \n                        \n                           \n                              Debossment\n                           \n                           \n                              \"10\" on one side of tablet \"TL\" on other side of tablet\n                           \n                           \n                              \"20\" on one side of tablet \"TL\" on other side of tablet\n                           \n                        \n                        \n                           \n                              \n                                 Presentations and NDC Codes\n                              \n                           \n                           \n                              Bottles of approximately 2520 tablets, NDC 55154-0256-8\n                           \n                           \n                              Bottles of approximately 2430 tablets, NDC 55154-0257-8",
    "adverseReactions_original": "\u2022Hypersensitivity to vortioxetine or any component of the formulation. Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with TRINTELLIX [see Adverse Reactions (6.2)].\n                     \n                        \u2022The use of MAOIs intended to treat psychiatric disorders with TRINTELLIX or within 21 days of stopping treatment with TRINTELLIX is contraindicated because of an increased risk of serotonin syndrome. The use of TRINTELLIX within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.4), Warnings and Precautions (5.2)]. Starting TRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2)]."
}